LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $20.00

Key Points

• BTIG Research raised its price target on LifeStance Health to $20 from $18 and reiterated a Buy rating, implying 48.7% upside from the prior close.
• LifeStance reported quarterly EPS of $0.06, beating estimates, while revenue rose 25.3% year over year to $455.9 million; the company also raised its full-year outlook.
• Analyst sentiment is broadly positive, with a Moderate Buy consensus, but the average price target is $13.38—below BTIG’s target.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) had its target price hoisted by equities researchers at BTIG Research from $18.00 to $20.00 in a report issued on Thursday, Benzinga reports. The firm presently has a "buy" rating on the stock. BTIG Research's target price would suggest a potential upside of 48.71% from the company's previous close.

Other research analysts also recently issued reports about the stock. JPMorgan Chase & Co. lifted their target price on shares of LifeStance Health Group from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, August 14th. Canaccord Genuity Group increased their price target on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Wednesday, September 9th. Wall Street Zen lowered shares of LifeStance Health Group from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 5th. Zacks Research cut shares of LifeStance Health Group from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 13th. Finally, Barclays upped their price objective on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company an "overweight" rating in a research note on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $13.38.

LifeStance Health Group Price Performance

NASDAQ LFST traded down $0.76 during trading hours on Thursday, reaching $13.45. 11,034,221 shares of the stock traded hands, compared to its average volume of 3,661,114. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38. The stock has a 50 day simple moving average of $12.56 and a two-hundred day simple moving average of $9.43. LifeStance Health Group has a 1 year low of $5.10 and a 1 year high of $15.66. The company has a market cap of $5.14 billion, a price-to-earnings ratio of 103.46 and a beta of 1.35.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.02. The company had revenue of $455.86 million for the quarter, compared to analysts' expectations of $431.59 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. The business's revenue was up 25.3% on a year-over-year basis. On average, analysts predict that LifeStance Health Group will post 0.16 EPS for the current fiscal year.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, CTO Vukasin Paunovich sold 44,394 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.85, for a total transaction of $481,674.90. Following the completion of the transaction, the chief technology officer owned 247,446 shares of the company's stock, valued at approximately $2,684,789.10. This trade represents a 15.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of LifeStance Health Group stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $10.62, for a total transaction of $144,890,858.34. Following the transaction, the insider owned 98,101,407 shares of the company's stock, valued at $1,041,836,942.34. The trade was a 12.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 13,777,580 shares of company stock valued at $146,433,781 in the last three months. Company insiders own 3.50% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in LFST. KBC Group NV purchased a new position in shares of LifeStance Health Group during the first quarter valued at approximately $29,000. IFP Advisors Inc lifted its position in LifeStance Health Group by 316.5% during the second quarter. IFP Advisors Inc now owns 3,694 shares of the company's stock valued at $40,000 after purchasing an additional 2,807 shares during the period. EverSource Wealth Advisors LLC lifted its position in LifeStance Health Group by 359.1% during the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company's stock valued at $44,000 after purchasing an additional 5,404 shares during the period. PNC Financial Services Group Inc. boosted its holdings in LifeStance Health Group by 615.3% in the first quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company's stock worth $59,000 after purchasing an additional 7,987 shares during the last quarter. Finally, Assetmark Inc. boosted its holdings in LifeStance Health Group by 17.0% in the first quarter. Assetmark Inc. now owns 9,419 shares of the company's stock worth $60,000 after purchasing an additional 1,367 shares during the last quarter. Hedge funds and other institutional investors own 85.50% of the company's stock.

LifeStance Health Group News Roundup

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q3 earnings were $0.06 per share, above estimates of $0.03–$0.04 and up from break-even a year earlier. Revenue rose 25.3% year over year to $455.9 million, topping the $431.6 million FactSet estimate. Zacks Q3 results
• Positive Sentiment: LifeStance raised its full-year outlook, adding to investor optimism about its growth and financial performance. Company earnings release

About LifeStance Health Group

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance's services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.